Awards Presented for Substantial Contributions to Cancer Research
LOS ANGELES, April 16 /PRNewswire-FirstCall/ -- Innovative and
collaborative cancer research can be the catalyst to improving patient
outcomes. Celebrating the 100th anniversary of the American Association for
Cancer Research (AACR) at the 2007 AACR Annual Meeting in Los Angeles, Eli
Lilly and Company in partnership with AACR presented two awards, which
acknowledge innovation and the growing importance of interdisciplinary
teams working together to transform research discoveries into clinical
practice.
"Both the Team Science Award and the G.H.A. Clowes Memorial Award allow
us to recognize individuals and teams who are working to bring meaningful
progress to the future of cancer care," said Richard Gaynor, M.D., vice
president, cancer research and global oncology platform leader at Lilly.
"Their work is occurring at hospitals, research organizations,
pharmaceutical and biotechnology companies and government institutions. The
breakthroughs delivered by these award recipients can form the backbone of
the next phase of cancer treatments. At Lilly, we are collaborating with
researchers around the world to identify the best ways to deliver the right
medication at the right dose and the right time for patients. This gives
the medical community and patients more powerful options in the fight
against cancer."
The first-ever Team Science Award was presented to a collaborative 16-
member team from the University of Michigan and Harvard University-Brigham
and Women's Hospital. The two universities worked together to uncover a
breakthrough finding -- a unique change involved in the pathogenesis of
prostate cancers -- which has profound clinical and biological implications
for understanding not just prostate cancer but possibly other common solid
tumors.
Selected from a pool of nearly 30 applicants, the Michigan and Harvard
team was collectively awarded a prize of $50,000. In addition to their
prize, the institutions will be cited for their collaboration and
contribution to team science.
Also presented was the G.H.A. Clowes Memorial Award recognizing an
individual with outstanding recent accomplishments in basic cancer
research. The award was presented to Michael Kastan, M.D., Ph.D., cancer
center director at St. Jude Children's Research Hospital in Memphis,
Tennessee, for his leadership in studying cellular responses to DNA damage.
Lilly and the AACR established the award in 1961 to honor Dr. G.H.A.
Clowes, a former research director at Lilly and an active member of AACR.
Dr. Kastan will be awarded $30,000 and will deliver a lecture on his
research findings during the 2007 AACR Annual Meeting.
"It is an honor to recognize Dr. Kastan with the Clowes Award and the
collaborative team from the University of Michigan and Harvard University
with the Team Science Award," said Gaynor. "Their work provides meaningful
knowledge of how we may be able to find new and innovative treatments to
combat this deadly disease."
About AACR
The mission of the American Association for Cancer Research is to
prevent and cure cancer. Founded in 1907, AACR is the world's oldest and
largest professional organization dedicated to advancing cancer research.
The membership includes more than 24,000 basic, translational, and clinical
researchers; health care professionals; and cancer survivors and advocates
in the United States and more than 70 other countries. AACR marshals the
full spectrum of expertise from the cancer community to accelerate progress
in the prevention, diagnosis and treatment of cancer through high-quality
scientific and educational programs. It funds innovative, meritorious
research grants. The AACR Annual Meeting attracts more than 17,000
participants who share the latest discoveries and developments in the
field. Special Conferences throughout the year present novel data across a
wide variety of topics in cancer research, treatment, and patient care.
AACR publishes five major peer- reviewed journals: Cancer Research;
Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer
Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent
publication, CR, is a magazine for cancer survivors, patient advocates,
their families, physicians, and scientists. It provides a forum for sharing
essential, evidence-based information and perspectives on progress in
cancer research, survivorship, and advocacy.
About Lilly Oncology, a Division of Eli Lilly and Company
For more than four decades, Lilly Oncology has been collaborating with
cancer researchers to deliver innovative treatment choices and valuable
programs to patients and their physicians. Inspired by courageous patients
living with cancer, Lilly Oncology is providing treatments that are
considered global standards of care and developing a broad portfolio of
novel targeted therapies to accelerate the pace and progress of cancer
care. To learn more about Lilly's commitment to cancer, please visit
http://www.LillyOncology.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs.
O-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)
SOURCE Eli Lilly and Company
 back to top
Related links:
http://www.LillyOncology.com/
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Christine Van Marter of Eli Lilly and
Company, +1-317-651-1473, or cell, +1-317-554-7923,
vanmarterch@lilly.com
|
